Nymox Pharmaceutical Corporation
NYMXF
Nymox Pharmaceutical Corporation is a biopharmaceutical company that focuses on the research and development of products primarily aimed at treating age-related medical conditions. The company's flagship product candidate is designed to treat benign prostatic hyperplasia (BPH), a condition that affects many older men. Nymox's mission is to improve the quality of life for patients by offering innovative therapeutic solutions that address significant unmet medical needs in the aging population. With its headquarters in Nassau, Bahamas, Nymox has been at the forefront of pharmaceuticals targeting prostate health, Alzheimer’s disease, and other areas impacting aging societies. The corporation's prominent focus and commitment to developing safe and effective treatments contribute significantly to healthcare advancements and opportunities within the global pharmaceutical market.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$4M
▲ +49.2% YoY
Op. Margin
–
ROIC
–
Cash Flow & Balance Sheet
FCF (TTM)
-$3M
▲ +35.9% YoY
Op. Cash Flow (TTM)
-$3M
▲ +35.9% YoY
Net Debt
-$74K
Net Cash Position
Cash & Equiv.
$74K
Continue Research
Peers
Biotechnology · Pick stocks to compare with NYMXF
Nymox Pharmaceutical (NYMXF) in three numbers
Questions about Nymox Pharmaceutical
Is Nymox Pharmaceutical a high-quality business?
Nymox Pharmaceutical scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from company filings. Its best check is net debt at -$74000, and its weakest is share count change at 14.3%. The Quality tab shows every check against its target.
Does Nymox Pharmaceutical (NYMXF) pay a dividend?
No. Nymox Pharmaceutical (NYMXF) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing NYMXF
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.